Stereotactic body radiotherapy (SBRT) is a treatment of high dose radiation in a single or small number fractions to the target areas.Compared with conventional radiotherapy,SBRT has the features of higher dose and better precision.The application in lung cancer can be summarized as the following three points:① SBRT has established the status of standard treatment for early (T1-2 N0 M0) nonsmall cell lung cancer (NSCLC) patients who unable or unwilling to undergo surgery.② The resuhs of preliminary application of SBRT in the operable NSCLC are not inferior to surgery.③ As for isolated metastases (1-3),the combination of systemic treatment and SBRT has been gradually accepted.This article makes a summary of this.

BACKGROUND: The improvement in production technology of new materials including artificial ligament reduces material rupture caused by fatigue and histocompatibility-related synovitis and other complications, leading to a wide application of artificial ligament. OBJECTIVE: To evaluate the histocompatibility and clinical curative effects of reconstruction of the anterior cruciate ligament (ACL) of the knee with ligament advanced reinforcement system (LARS) artificial ligament using arthroscopy. DESIGN: A completely randomized clinical design. SETTING: Department of Orthopedics, Second Affiliated Hospital of Soochow University. PARTICIPANTS: Thirty-two cases of ACL injury received LARS artificial ligament in the Department of Orthopedics, Second Affiliated Hospital of Soochow University From June 2005 to June 2006 and were recruited for this study. The 32 patients averaged 21 years old and were injured in sports. Prior to surgery, MRI showed injury to ACL and semilunar valve in all patients. Written informed consent for therapeutic contents was obtained from each patient. METHODS: Thirty-two patients with injury to ACL of the knee underwent arthroscopic ACL reconstruction. LARS was used to reconstruct the ACL. The LARS was produced by Laboratoire d'Application et de Recherche Scientifique, France (Certification No. CE0459, 1SO9002-EN46002). Artificial ligament was made of polyethylene terephthalate, which had the material type L021201 (left knee) and L021202 (right knee). Artificial ligament was designed to imitate the anatomic structure and biomechanical principle of artificial ligament with specification No. AC120 2BL(left knee) and No. AC120 2BR(right knee). The lot number for artificial ligament in China [import 03460468 (in 2004)]. All reconstructions were performed by a group of physicians who have worked for more than 10 years in the Department of Orthopedics, Second Affiliated Hospital of Soochow University and directed by a physician titled with doctor's tutor and chief physician. All included physicians were qualified to perform the surgery. The protocol of treatment was approved by the hospital's Ethics Committee. MAIN OUTCOME MEASURES: Biocompatibility of LARS artificial ligament was observed. Patients were followed up for 24 months on average to score knee function by Lysholm test and subjective satisfaction by Tegner test. RESULTS: All of 32 cases were followed up. The follow-up periods were 18 months (3 cases), 20 months (7 cases), 24 months (8 cases), 28 months (12 cases) and 30 months (2 cases). No complications, such as acute or chronic synovitis, LARS artificial ligament rupture, or limited range of motion were found. The knee joint function was ideal with the range of motion [0° to (128±11.56)°]. The postoperative scores with 85.6 ± 2.24 were significandy higher than the preoperative scores with 45.3±1.31 according to the Lysholm knee joint function evaluation system (P < 0.05). The instability of every knee disappeared with anterior drawer sign negative. Tegner's scores were also increased. CONCLUSION: The biocompatibility of LARS is optimal. LARS artificial ligament reconstruction showed excellent knee joint function and subjective satisfaction degree.

BACKGROUND: Of the many growth factors that can enhance bone formation, the bone morphogenic proteins (BMPs) are probably the most effective and most widely studied for applications requiring new bone growth. To analyze the effects, the gold standard is patient randomized control trials, however, only BMP-2 and BMP-7 have reached this level of investigation. OBJECTIVE: In this meta analysis the recent findings concerning the application of recombinant human bone morphogenic protein-2 (rhBMP-2) in tissue engineering and gene therapy, the options of its transfer means, as well as the ideal time of delivery is discussed. RETRIEVAL STRATEGY: The relevant articles published between January 1997 and December 2006 were searched for in Pubmed database by researcher of this article with the key words "recombinant human bone morphogenic proteins (rhBMPs), tissue engineering, gene therapy" in English. A total of 81 articles were selected and reviewed by the standards of: ① Having close relations with the application of rhBMP-2 in tissue engineering and gene therapy; ②The most recently published articles and articles in authority journals were chosen in the same field. Exclusion criteria: repetitive studies. LITERATURE EVALUATION: The main sources of literature are the application of rhBMP-2 in tissue engineering and gene therapy. Among the 52 selected articles, 12 are reviews or meeting reports, others are clinical or elementary experimental studies. DATA SYNTHESIS: BMPs are members of the TGF- β superfamily, which are released by osteoprogenitor cells and typically improve bone growth. The use of scaffolds, cells, and growth factors for bone regeneration is called bone tissue engineering. The application of rhBMP-2 in tissue engineering holds great promise for the augmentation and manipulation of bone and soft tissue repair. One potential alternative to direct rhBMP-2 delivery is to develop a biologic cellular delivery vehicle via gene therapy to enhance bone formation. The application of rhBMP-2 in gene therapy holds great promise for the augmentation and manipulation of bone and soft tissue repair. The research indicated that the dosing, time, and transfer mode of rhBMP-2 to the desired targets remain a facing challenge. Further studies should focus on the ideal dosing, time and method of delivery, which should be easily and reliably displayed, cost effective, and clearly controlled. CONCLUSION: The future of bone and soft tissue repair will likely be based on biologic augmentation of healing and tissue regeneration. The use of rhBMP-2 holds great promise for the augmentation and manipulation in tissue engineering and gene therapy.

Humans ; Mouth Diseases ; classification ; diagnosis ; therapy ; Mouth Mucosa ; pathology ; Oral Medicine ; standards ; Reference Standards

Objective To evaluate the impact osteolytic cytokines of expression induced by micrometer-diameter wear particles(Ti-6Al-4V and UHMWPE).Methods Filtration air was subcutaneously injected into rats'back 6 times(3 mL q?d).After a week,wear particles suspension(group A: Ti-6Al-4V,group B: UHMWPE) or physiological saline(group C) was injected into air pouch tissues.After 14 days,pouch tissues were obtained from killed rats,and were weighted,wax embedded and stained with hematoxylin and eosin, observed under microscope.AKP of serium with Automated Biochemical Analyzer,IL-6 and TNF-? expression with immunohistochemical method,and mRNA expression of extracellular matrix metalloproteinase inducer(EMMPRIN) with real-time Polymerase Chain Reaction method were detected.Results Air pouch tissues were similar to limiting membrane of periprothesis tissue in the cases of aseptic loosening.As to pouch tissue weight,there was a significant increase in group B than in group C(P

Objective To study the relationship between hyperhomocysteinemia and type 2 diabetes patients with cerebral infarction and its influencing factors.Methods Serum homocysteine levels were measured by high performance liquid chromatography (HPLC) in type 2 diabetes patients with cerebral infarction (DS group), type 2 diabetes patients without complications (DNC group) and normal control subjects. Plasma folate and VitB 12 concentrations were detected by radioimmune assay.Results The levels of homocysteine in DS group and DNC group were significantly higher than in normal control group (all P

Objective To evaluate the efficacy and safety of imiquimod 5% cream applied with different treatment courses for preventing the recurrence of condyloma acuminatum lesions.Methods A randomized,controlled clinical trial was conducted.Patients with condyloma acuminatum were divided into 3 groups (Group A,B and C).Group A was treated with CO2 laser only.Group B was given topical im- iquimod 5% cream three times a week over 4 weeks after laser treatment of visible warts.Group C was giv- en topical imiquimod 5% cream three times a week over 8 weeks after laser treatment of visible warts.All patients were followed up for 6 months.Results A total of 90 patients with anogenital warts were enrolled in,and finished the study.The recurrence rates of the Group A,B,and C were 64.29%,50%,21.88%,re- spectively,in 6 months of follow-up.The recurrence rate was statistically lower in Group C than in Group A and B (P=0.0033),and in Group C than in Group B (P=0.0457).Adverse reactions occurred in 73.33% and 84.38% of patients in Group B and C,respectively,which included erythema,itching,pain, burning,erosion,ulceration and flu-like symptoms.There was no significant difference of the frequencies of adverse reactions between Group B and C (P＞0.05).Conclusion The recurrence rate of anogenital warts declines significantly in patients treated with imiquimod 5% cream for 8 weeks,but not in the 4 weeks group,after laser therapy.The frequencies of adverse reactions are not significantly different in both groups.

Acetates ; blood ; Adult ; Aged ; Chromatography, Gas ; methods ; Female ; Humans

Objective To explore a simple and effective way of establishing a mice orthotopic tracheal transplantation model in studying bronchiolitis obliterans to reduce operation time. Methods Tracheas from C57BL/6 mice (n=30) were im?planted into Balb/c mice (n=30). Grafts and hosts were matched according to body weight.Orotracheal intubation and endo-stentwas used for trachea anastomose and animal model was establish. Operating time was also noted. Grafts were harvest?ed on Days 15, 30 and 60 after transplantation, using HE staining to observe pathological changes of allograft. Trachea block?ing rate was also calculated. Results Until survival of trachea transplantation, the operative time of donor′s and the recipi?ent′tracheas resection were (7.0±1.0) min and (7.0±1.0) min respectively.Orotracheal intubation the endo-stentestablish?ment cost(1 ± 0.5)min. Trachea anastomose took(20.0 ± 4.0)min and the operation time last(43.0 ± 10.0)min. Conclusion The improvement of orthotopic tracheas transplantation usingOrotracheal intubation the endo-stenfor trachea anastomose is esay-operated and did required complicate skills and instruments with high successful rate. So it is an ideal and stable model in studying bronchiolitis obliterans.

BACKGROUND:There were stil lacking related clinical researches in the aspects of whether the total blood loss and hidden blood loss were connected with pathogenesis, whether the total blood loss and hidden blood loss were different among the patients who conducted total hip arthroplasty under different pathogenesis, and whether the preoperative intervention should be conducted for a particular cause? OBJECTIVE:To compare and analyze the hidden blood loss of patients with hip osteoarthritis and femoral neck fracture after total hip replacement. METHODS:The clinical data of 150 patients who received the unilateral total hip arthroplasty treatment from June 2013 to January 2015 were colected and analyzed, including 54 patients with hip osteoarthritis (30 male cases and 24 female cases ), 96 patients with femoral neck fracture (41 male cases and 55 female cases). The pre-and post-operative blood routine and intro-and post-operative blood loss and transfusion were recorded, and hidden blood loss during pen-operation period was evaluated. RESULTS AND CONCLUSION:Total blood loss was (1 616±216) mL, hidden blood loss was (699±102) mL, and hidden blood loss accounted for 43.3% of the total blood loss. The total blood loss was (1 742±254) mL in the hip osteoarthritis group, hidden blood loss was (758±127) mL, hidden blood loss accounted for 44.6% of the total blood loss; The average total blood loss was (1 470±189) mL in the femoral neck fracture group, hidden blood loss was (625±98) mL, hidden blood loss accounts for 42.1% of the total blood loss. The total blood loss and hidden blood loss in hip osteoarthritis group were significantly higher than those in the femoral neck fracture group (P< 0.05). However, there was no significant difference on the hidden blood loss accounts for the proportion of the total blood loss between two groups (P=0.419 3). These results suggest that the total blood loss and hidden blood loss are different for the patients who underwent total hip arthroplasty in the premise of both pathogenesis. Therefore, before the total hip arthroplasty, we should fuly take into account the primary cause of patients and estimate the total blood loss and hidden blood loss, so as to take appropriate preventive measures in time to ensure the safety of the replacement process.